Funding Clinical Trials
Funding Clinical Trials (Panel)
- Joan Koerber-Walker-Moderator (AZBio)
- Terry Urbine, PhD (Assistant Research Scientist, UA College of Pharmacy)
- Jeremy Shefner, MD, PhD (Barrow Department of Neurology Chair and Associate Director for Barrow Neurological Institute)
- Teresa Bartels (President, Gateway for Cancer Research)
2017 Fast Lane Honoree Rowpar Pharmaceuticals
According to the Mayo Clinic, like many areas of the body, your mouth is teeming with bacteria — most of them harmless. Normally the body's natural defenses and good oral health care, such as daily brushing and flossing, can keep these bacteria under control. Many chronic systemic diseases have been linked to bacteria originating in the mouth. The Rowpar Pharmaceuticals team believes that oral care needs to be more than just about fresh breath and whiter teeth. ClōSYS is about reducing oral pathogens associated with oral and systemic diseases while not impeding the healing process and not disrupting the oral ecology. Fresh breath and whiter teeth are a bonus ClōSYS delivers. Headquartered in Scottsdale, Arizona since 1991, Rowpar Pharmaceuticals, Inc. is an organization dedicated to providing innovative oral health solutions. ClōSYS® Oral Health products help people live healthier lives.
AZBio and SynCardia on ABC15
By: Christina Estes ABC15
Tucson-based SynCardia Systems was among the companies showcased at the annual AZ Bio Expo.It’s a chance for bioscience and technology companies to learn more about funding opportunities and hear success stories.According to the Arizona BioIndustry Association, our state is getting more federal funding for research and seeing higher job growth in the bioscience industry compared to the national average.“Tucson and Arizona are the international headquarters for the world’s only total artificial heart,” said Don Isaacs, SynCardia vice president of communications. “They replace the exact same parts of the heart as if you had a heart transplant.”The SynCardia heart is made in Arizona using bio-compatible material also made here. Isaacs says they have 82 employees in Arizona and about 80 people currently using the heart. The device is considered a bridge for people awaiting a transplant or a life saver for those who will not get transplants due to age or medical conditions.“There’s only 2,200 hearts available per year in the United States and the level of donors has been the same for the last twenty years,” Isaacs said.SynCardia is also undergoing FDA clinical trials for the world’s first wearable power supply for their temporary artificial heart.
(Republished with permission from ABC15)
Read more: http://www.abc15.com/dpp/news/region_southeast_valley/tempe/Arizona-company-SynCardia-Systems-makes-worlds-first-total-temporary-artificial-heart#ixzz2X99ewU3x